A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). (Q52033532)
Jump to navigation
Jump to search
scientific article published in July 1999
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). |
scientific article published in July 1999 |
Statements
1 reference
A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). (English)
1 reference
F Forette
1 reference
R Anand
1 reference
G Gharabawi
1 reference
1 July 1999
1 reference
6
1 reference
423-429
1 reference
4
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference